论文部分内容阅读
目的探讨雷公藤片治疗类风湿关节炎(RA)的临床疗效及安全性。方法选取2014年11月—2016年11月60例广州市番禺区中医院收治的病情处于活动期RA的患者,随机分为对照组和观察组,每组30例。对照组给予口服甲氨蝶呤和美洛昔康治疗,观察组在对照组的治疗基础上加用雷公藤片,对两组血液样本进行理化指标血沉(ESR),类风湿因子滴度(RF)、C反应蛋白(CRP)检查,监测患者免疫学指标免疫球蛋白(Ig G,Ig M),并对两组患者治疗8周后的不良反应发生情况进行比较。结果观察组总有效率(89.57%)明显高于对照组(80.44%),调节患者免疫功能的作用均优于对照组(P<0.05);观察组不良反应发生率23.33%(7/30),对照组26.67%(8/30),两组比较差异无统计学意义(χ~2=0.09,P>0.05)。结论临床治疗RA患者的过程中,雷公藤片能显著调节患者免疫功能,不增加患者的不良反应发生率。
Objective To investigate the clinical efficacy and safety of Tripterygium tablets in the treatment of rheumatoid arthritis (RA). Methods From November 2014 to November 2016, 60 patients with active RA in Panyu District Chinese Medicine Hospital of Guangzhou were randomly divided into control group and observation group, 30 cases in each group. The control group was treated with oral methotrexate and meloxicam. The observation group was given Tripterygium wilfordii root tablets on the basis of the treatment of the control group, and the physical and chemical indexes ESR, RF of the rheumatoid factor, , C-reactive protein (CRP) were detected, immunoglobulin (Ig G, Ig M) was monitored in patients. The incidence of adverse reactions was compared between the two groups after 8 weeks of treatment. Results The total effective rate (89.57%) in the observation group was significantly higher than that in the control group (80.44%), and the immune function was better than the control group (P <0.05). The incidence of adverse reactions in the observation group was 23.33% (7/30) , And 26.67% (8/30) in the control group. There was no significant difference between the two groups (χ ~ 2 = 0.09, P> 0.05). Conclusion In the clinical treatment of RA patients, Tripterygium tablets can significantly adjust the patient’s immune function, does not increase the incidence of adverse reactions in patients.